First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Portfolio Pulse from
Aptevo Therapeutics announced that the first patient in their RAINIER trial for mipletamig, a potential frontline treatment for Acute Myeloid Leukemia (AML), achieved a 90% reduction in leukemic blasts within 30 days. This continues the positive trend seen in previous studies, highlighting mipletamig's potential when combined with standard treatments.
November 20, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptevo Therapeutics' RAINIER trial for mipletamig shows promising results with a 90% reduction in leukemic blasts in the first patient, indicating potential for redefining AML treatment.
The news highlights a significant milestone in Aptevo's RAINIER trial, with the first patient showing a 90% reduction in leukemic blasts. This positive result supports the potential of mipletamig as a frontline treatment for AML, which could lead to increased investor confidence and a positive impact on APVO's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100